Skip to main content
Clinical Trials/DRKS00004521
DRKS00004521
Completed
Phase 2

Translational therapy in patients with osteogenesis imperfecta - a pilot trial on treatment with the RANKL-antibody Denosumab - OI-AK

Klinik und Poliklinik für Kinder- und Jugendmedizin0 sites10 target enrollmentFebruary 15, 2013

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Q78.0
Sponsor
Klinik und Poliklinik für Kinder- und Jugendmedizin
Enrollment
10
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 15, 2013
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Klinik und Poliklinik für Kinder- und Jugendmedizin

Eligibility Criteria

Inclusion Criteria

  • Male or female subjects between 5 years and 10 years of age with molecular proven Osteogenesis imperfecta (COL1A1/2 mutation)
  • Subjects must have been treated for a minimum of 2 years with i.v. bisphosphonates prior to study entry

Exclusion Criteria

  • Hypocalcemia (\<1\.03 mmol/l ionized Calcium)
  • Subjects with reduced renal function (estimated GFR (Schwartz formula) \<30ml/min/1\.73m2\)
  • Any other abnormal finding such as physical examination or laboratory evaluation, in the opinion of the investigator that is indicative of a disease that would compromise the safety of the patient when getting Denosumab s.c.

Outcomes

Primary Outcomes

Not specified

Similar Trials